Management of primary cutaneous CD4
1 small and medium pleomorphic T-cell lymphoma: A retrospective study To the Editor: Primary cutaneous small and medium CD4 1 T-cell lymphoma (CD4 1 PCSM-TCL) is a rare variant of T-cell lymphoproliferative disorder accounting for 2% of all primary cutaneous lymphomas. 1 Clinically, this lymphoma is generally indolent and presents as a solitary papule, plaque, or nodule predominantly on the face, neck, or upper trunk. 1 On histologic analysis, it is characterized by a dense, nodular or diffuse lymphocytic infiltrate in the dermis. In the 2016 World Health Organization (WHO) classification, CD4
1 PCSM-TCL is categorized as a primary cutaneous small-or medium-sized T-cell lymphoproliferative disorder given its indolent behavior and favorable outcomes. 2 However, no standard of care was established due to its rarity.
We retrospectively reviewed a cohort of 684 patients with a diagnosis of cutaneous lymphoma Seven patients were treated with local excision alone. Three patients received electron radiation therapy (RT) alone, and 1 patient with 4 lesions was treated with both excision and RT. The median RT dose administered was 33 (range 22.5-36) Gy in 1.8-3 Gy/fraction. All patients achieved complete remission. These findings are similar to 2 previously published case series, highlighting that local failure is not frequently observed in daily practice. 3, 4 Our data confirmed that surgical excision and RT can be used as primary treatment modalities for CD4
1 PCSM-TCL.
In the present series, 2 patients with 4 lesions and 2 patients with 2 lesions achieved complete remission after local treatments targeted to each individual lesion site. Previously, it was suggested that multifocal disease might have a different clinical behavior from that of solitary lesions. 3 Our data suggests that irrespective of multiple lesions localized treatment modalities are also suitable for this group of patients.
Selected studies with available treatment approaches and clinical outcomes were reviewed using PubMed (Table II) . In total, 135 patients were identified; 41 patients were treated with localized RT alone, and 53 patients received local excision alone. Other treatment approaches (eg, administration of steroids, combination of RT and excision, and chemotherapy) are described in Table II . Overall, at a median follow-up of 24 months, 109 patients (80.7%) obtained complete remission.
Because CD4 1 PCSM-TCL is most often indolent with rare systemic involvement, the condition should be primarily managed with localized treatment. This clinical course is different from that of mycosis fungoides, of which ;1 in 3 cases is associated with extracutaneous dissemination requiring more aggressive treatment regimens. 
